WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H328306
CAS#: 191114-48-4
Description: Telithromycin, also known as HMR-3647 and RU-66647, is a semi-synthetic erythromycin derivative used to treat mild to moderate respiratory infections.
Hodoodo Cat#: H328306
Name: Telithromycin
CAS#: 191114-48-4
Chemical Formula: C43H65N5O10
Exact Mass: 811.47
Molecular Weight: 812.018
Elemental Analysis: C, 63.60; H, 8.07; N, 8.62; O, 19.70
Synonym: Telithromycin; HMR-3647; HMR 3647; HMR3647; RU-66647; RU 66647; RU66647
IUPAC/Chemical Name: (3aS,4R,7R,9R,10R,11R,13R,15R,15aR)-10-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-4-ethyl-11-methoxy-3a,7,9,11,13,15-hexamethyl-1-(4-(4-(pyridin-3-yl)-1H-imidazol-1-yl)butyl)octahydro-2H-[1]oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetraone
InChi Key: LJVAJPDWBABPEJ-PNUFFHFMSA-N
InChi Code: InChI=1S/C43H65N5O10/c1-12-33-43(8)37(48(41(53)58-43)19-14-13-18-47-23-31(45-24-47)30-16-15-17-44-22-30)27(4)34(49)25(2)21-42(7,54-11)38(28(5)35(50)29(6)39(52)56-33)57-40-36(51)32(46(9)10)20-26(3)55-40/h15-17,22-29,32-33,36-38,40,51H,12-14,18-21H2,1-11H3/t25-,26-,27+,28+,29-,32+,33-,36-,37-,38-,40+,42-,43-/m1/s1
SMILES Code: O=C([C@H](C)C[C@@](C)(OC)[C@H](O[C@@H]1O[C@H](C)C[C@H](N(C)C)[C@H]1O)[C@@H](C)C([C@@H](C)C(O[C@H](CC)[C@@]2(C)O3)=O)=O)[C@H](C)[C@@]2([H])N(CCCCN4C=C(C5=CC=CN=C5)N=C4)C3=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 812.02 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Uzun B, Güngör S, Pektaş B, Aksoy Gökmen A, Yula E, Koçal F, Kaya S. [Macrolide-lincosamide-streptogramin B (MLSB) resistance phenotypes in clinical Staphylococcus isolates and investigation of telithromycin activity]. Mikrobiyol Bul. 2014 Jul;48(3):469-76. Turkish. PubMed PMID: 25052113.
2: Ikawa K, Kikuchi E, Kikuchi J, Nishimura M, Derendorf H, Morikawa N. Pharmacokinetic modelling of serum and bronchial concentrations for clarithromycin and telithromycin, and site-specific pharmacodynamic simulation for their dosages. J Clin Pharm Ther. 2014 Aug;39(4):411-7. doi: 10.1111/jcpt.12157. Epub 2014 Mar 24. PubMed PMID: 24661290.
3: Shoji T, Takaya A, Sato Y, Kimura S, Suzuki T, Yamamoto T. RlmCD-mediated U747 methylation promotes efficient G748 methylation by methyltransferase RlmAII in 23S rRNA in Streptococcus pneumoniae; interplay between two rRNA methylations responsible for telithromycin susceptibility. Nucleic Acids Res. 2015 Oct 15;43(18):8964-72. doi: 10.1093/nar/gkv609. Epub 2015 Sep 13. PubMed PMID: 26365244; PubMed Central PMCID: PMC4605293.
4: Telithromycin: review of adverse effects. Prescrire Int. 2014 Nov;23(154):264-6. PubMed PMID: 25954793.
5: Blondeau JM, Shebelski SD, Hesje CK. Killing of Streptococcus pneumoniae by azithromycin, clarithromycin, erythromycin, telithromycin and gemifloxacin using drug minimum inhibitory concentrations and mutant prevention concentrations. Int J Antimicrob Agents. 2015 Jun;45(6):594-9. doi: 10.1016/j.ijantimicag.2014.12.034. Epub 2015 Feb 16. PubMed PMID: 25752567.
6: Glassford I, Lee M, Wagh B, Velvadapu V, Paul T, Sandelin G, DeBrosse C, Klepacki D, Small MC, MacKerell AD Jr, Andrade RB. Desmethyl macrolides: synthesis and evaluation of 4-desmethyl telithromycin. ACS Med Chem Lett. 2014 Jul 16;5(9):1021-6. doi: 10.1021/ml5002097. eCollection 2014 Sep 11. PubMed PMID: 25221660; PubMed Central PMCID: PMC4160760.
7: Togami K, Hayashi Y, Chono S, Morimoto K. Involvement of intestinal permeability in the oral absorption of clarithromycin and telithromycin. Biopharm Drug Dispos. 2014 Sep;35(6):321-9. doi: 10.1002/bdd.1900. Epub 2014 Jun 27. PubMed PMID: 24801141.
8: Park B, Min YH. Inducible expression of erm(B) by the ketolides telithromycin and cethromycin. Int J Antimicrob Agents. 2015 Aug;46(2):226-7. doi: 10.1016/j.ijantimicag.2015.05.001. Epub 2015 Jun 3. PubMed PMID: 26088553.
9: Vimberg V, Lenart J, Janata J, Balikova Novotna G. ClpP-independent function of ClpX interferes with telithromycin resistance conferred by Msr(A) in Staphylococcus aureus. Antimicrob Agents Chemother. 2015;59(6):3611-4. doi: 10.1128/AAC.04367-14. Epub 2015 Mar 23. PubMed PMID: 25801573; PubMed Central PMCID: PMC4432155.
10: Li XM, Wang FC, Yang F, Jin YH. Telithromycin versus clarithromycin for the treatment of community-acquired respiratory tract infections: a meta-analysis of randomized controlled trials. Chin Med J (Engl). 2013;126(11):2179-85. PubMed PMID: 23769580.
